WASHINGTON, D.C. - Saying there will be hundreds or thousands of lawsuits involving claims that three incretin mimetic anti-diabetes drugs cause pancreatic cancer, two plaintiffs on April 5 asked the Judicial Panel on Multidistrict Litigation (JPMDL) to centralize the 53 filed federal cases before one judge (In Re: Incretin Mimetics Product Liability Litigation, MDL Docket No. 2452, JPMDL)....(read more)![]()
↧